CytoSorbents Corporation (CTSO)

[techxen]

REMOVE trial (https://www.drks.de/DRKS00013740)
I learned something new now. The studies posted on the German Clinical Trial Register, have the actual protocol documents attached to the entry. CG pointed this out on YMB.

I downloaded the .pdf for the REMOVE trial which is CTSO's largest randomized trial to date (288 patients) and looked through the doctors involved. Below was my response to him concerning one of the US doctors on the DSMB - Dr. Matthias Loebe. This guy has some very impressive credentials!


"@Techxen, Yeah, that looks like a new study that has yet to be registered anywhere else (like on clinicaltrials.gov). There's several planned trials that we've heard about at various conferences that we've yet to see appear on clinicaltrials.gov. In general, you can find a lot of information on the German clinical trials site. For example, for REMOVE, the whole clinical trial protocol is available (both v1 and v2), and I was able to determine that 2 of the 3 physicians on the DSMB are American, including Dr. John Kellum from U. of Pittsburg and Dr. Matthias Loebe from U. of Miami (the 3rd physician is Dr. Peter U. Heuschmann from U. of Wu¨rzburg in Germany).

@CG I didn't see that before that the trial protocols and approvals were actually attached to the entry. That is great information. I looked up Dr. Loeb because I have not seen his name attached to any previous Cytosorb studies, and it appears he graduated from medical school at the Free University Berlin Germany and did his internship at University Hospital in Zurich and residency at German Heart Institute in Berlin, so I see the German connection here. He has been around, previously serving as professor of cardiovascular surgery at Weill Cornell Medical College in New York City, and as Director and Chief of Thoracic Transplantation at the Methodist DeBakey Heart and Vascular Institute in Houston. He was also Surgical Director of the Center for Difficult Airway and Pleural Surgery at Baylor College of Medicine, which is home to one of the busiest heart, lung and heart-lung transplant programs in the country. He has developed groundbreaking cardiac surgery techniques in the U.S. and Germany and has performed vital research on organ replacement and lung disease, and his work has led to the implementation of second-generation ventricular assist devices. Having him on this board might be beneficial with his US connections."

http://www.med.miami.edu/news/dr.-matthias-loebe-joins-miami-transplant-institute